- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14.10. | Pfizer drug for hemophilia approved by FDA | ||
| 14.10. | Successful COA selection paves the path to drug development | ||
| 14.10. | From maximizing recruitment to promoting diversity: How to deploy NGS technologies to achieve clinical trial success | ||
| 14.10. | Choosing the right hub partner: A blueprint for decision-makers | ||
| 11.10. | Sanofi may have found a buyer for its consumer health business | ||
| 11.10. | FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff | ||
| 11.10. | Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug | ||
| 10.10. | UnitedHealth, CVS push to remove FTC Chair Lina Khan from PBM case | ||
| 10.10. | Ex-Pfizer execs 'threatened' for supporting plans to shake up company, Starboard says | ||
| 10.10. | The number of AI medical devices has spiked in the past decade | ||
| 10.10. | Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. | ||
| 10.10. | New data underline cancer risk of Bluebird therapy for brain disease | ||
| 09.10. | Purespring raises $105M to advance gene therapy for kidney disease | ||
| 09.10. | Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application | ||
| 09.10. | Lilly partners with AI specialist Insitro to develop metabolic medicines | ||
| 09.10. | Lilly names Mount Sinai scientist as first chief AI officer | ||
| 09.10. | AI startup Basecamp allies with the Broad to dream up 'programmable' genetic medicines | ||
| 09.10. | Using de-identified lab data to find patients, target physicians and expedite treatment | ||
| 08.10. | Sage continues downslide as Alzheimer's study fails | ||
| 08.10. | GSK says RSV vaccine protects against disease over three seasons | ||
| 08.10. | Startup led by John Maraganore raises $135M to build 'future of RNAi' | ||
| 07.10. | GSK's ViiV to expand supply of HIV drug in Africa | ||
| 07.10. | Scholar Rock scores with 'surprise' success in SMA drug study | ||
| 07.10. | Intellia starts late-stage test of CRISPR therapy for rare swelling disease | ||
| 07.10. | Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
